Janux Therapeutics, Inc. Capital Expenditures
Janux Therapeutics, Inc. (JANX) reported Capital Expenditures of $475.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $202.00K, a 57.29% decline year-over-year.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $273.00K, a 26.42% decline year-over-year.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $106.00K, a 152.38% increase year-over-year.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $93.00K, a 272.00% increase year-over-year.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $1.04M, a 190.53% increase from fiscal 2024.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $359.00K, a 80.59% decline from fiscal 2023.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $1.85M, a 71.30% decline from fiscal 2022.
- Janux Therapeutics, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $6.45M, a 334.89% increase from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 12 month |
|---|---|---|---|---|
| 2026-06-30 | $202.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $475.00K 10-Q · filed 2026-08-06 | $581.00K derived: sum of 3 quarters · filed 2026-08-06 | $674.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $273.00K 10-Q · filed 2026-05-07 | $379.00K derived: sum of 2 quarters · filed 2026-05-07 | $472.00K derived: sum of 3 quarters · filed 2026-05-07 | $945.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $106.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $199.00K derived: sum of 2 quarters · filed 2026-02-26 | $672.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.04M 10-K · filed 2026-02-26 |
| 2025-09-30 | $93.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $566.00K derived: sum of 2 quarters · filed 2026-08-06 | $937.00K 10-Q · filed 2025-11-06 | $979.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $473.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $844.00K 10-Q · filed 2026-08-06 | $886.00K derived: sum of 3 quarters · filed 2026-08-06 | $911.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $371.00K 10-Q · filed 2026-05-07 | $413.00K derived: sum of 2 quarters · filed 2026-05-07 | $438.00K derived: sum of 3 quarters · filed 2026-05-07 | $533.00K derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $42.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $67.00K derived: sum of 2 quarters · filed 2026-02-26 | $162.00K derived: sum of 3 quarters · filed 2026-02-26 | $359.00K 10-K · filed 2026-02-26 |
| 2024-09-30 | $25.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $120.00K derived: sum of 2 quarters · filed 2025-11-06 | $317.00K 10-Q · filed 2025-11-06 | $832.00K derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $95.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $292.00K 10-Q · filed 2025-08-07 | $807.00K derived: sum of 3 quarters · filed 2026-02-26 | $1.28M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $197.00K 10-Q · filed 2025-05-08 | $712.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.18M derived: sum of 3 quarters · filed 2026-02-26 | $1.76M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $515.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $985.00K derived: sum of 2 quarters · filed 2026-02-26 | $1.56M derived: sum of 3 quarters · filed 2026-02-26 | $1.85M 10-K · filed 2026-02-26 |
| 2023-09-30 | $470.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $1.05M derived: sum of 2 quarters · filed 2024-11-06 | $1.33M 10-Q · filed 2024-11-06 | $3.39M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $580.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $865.00K 10-Q · filed 2024-08-07 | $2.92M derived: sum of 3 quarters · filed 2025-02-27 | $5.44M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $285.00K 10-Q · filed 2024-05-08 | $2.34M derived: sum of 2 quarters · filed 2025-02-27 | $4.86M derived: sum of 3 quarters · filed 2025-02-27 | $5.76M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $2.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $4.58M derived: sum of 2 quarters · filed 2025-02-27 | $5.47M derived: sum of 3 quarters · filed 2025-02-27 | $6.45M 10-K · filed 2025-02-27 |
| 2022-09-30 | $2.52M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | $3.42M derived: sum of 2 quarters · filed 2023-11-07 | $4.39M 10-Q · filed 2023-11-07 | $5.56M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $898.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.87M 10-Q · filed 2023-08-08 | $3.04M derived: sum of 3 quarters · filed 2023-08-08 | $3.12M derived: sum of 4 quarters · filed 2023-08-08 |
| 2022-03-31 | $971.00K 10-Q · filed 2023-05-09 | $2.14M derived: sum of 2 quarters · filed 2023-05-09 | $2.22M derived: sum of 3 quarters · filed 2023-05-09 | $2.30M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-10 | $1.25M derived: sum of 2 quarters · filed 2023-03-10 | $1.33M derived: sum of 3 quarters · filed 2023-03-10 | $1.48M 10-K · filed 2023-03-10 |
| 2021-09-30 | $77.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $156.00K derived: sum of 2 quarters · filed 2022-11-10 | $309.00K 10-Q · filed 2022-11-10 | $309.00K derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $79.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $232.00K 10-Q · filed 2022-08-09 | $232.00K derived: sum of 3 quarters · filed 2022-08-09 | $232.00K derived: sum of 4 quarters · filed 2022-08-09 |
| 2021-03-31 | $153.00K 10-Q · filed 2022-05-10 | $153.00K derived: sum of 2 quarters · filed 2022-05-10 | $153.00K derived: sum of 3 quarters · filed 2022-05-10 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-18 | $0.00 derived: sum of 2 quarters · filed 2022-03-18 | $0.00 10-K · filed 2022-03-18 | |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $0.00 10-Q · filed 2021-11-09 | ||
| 2020-06-30 | $0.00 10-Q · filed 2021-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Jade Biosciences, Inc. (JBIO) | United States | $0.936B | -9.21 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |